Affiliated Managers Group, Inc., through its affiliates, operates as an investment management company providing investment management services to mutual funds, institutional clients,retails and high net worth individuals in the United States. It provides advisory or sub-advisory services to mutual funds. These funds are distributed to retail, high net worth and institutional clients directly and through intermediaries, including independent investment advisors, retirement plan sponsors, broker-dealers, major fund marketplaces, and bank trust departments. The company also offers investment products in various investment styles in the institutional distribution channel, including small, small/mid, mid, and large capitalization value and growth equity, and emerging markets. In addition, it offers quantitative, alternative, and fixed income products, and manages assets for foundations and endowments, defined benefit, and defined contribution plans for corporations and municipalities. Affiliated Managers Group provides investment management or customized investment counseling and fiduciary services. Affiliated Managers Group, Inc. was formed in 1993 and is based in West Palm Beach, Florida with additional offices in Prides Crossing, Massachusetts; Stamford, Connecticut; London, United Kingdom; Dubai, United Arab Emirates; Sydney, Australia; Hong Kong; Tokyo, Japan, Zurich, Switzerland and Delaware.

Affiliated Managers Group Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), ProQR (PRQR) and Spyre Therapeutics ...

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), ProQR (PRQR) and Spyre Therapeutics (SYRE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN) and Healthequity (HQY). Amgen (AMGN) ...

Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and Healthequity (HQY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN) and Healthequity (HQY). Read More on AMGN: Amgen pri...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Healthequity (HQY)

Goldman Sachs analyst Alexander Blostein maintained a Buy rating on Affiliated Managers yesterday and set a price target of $367.00. According to T...

Goldman Sachs Remains a Buy on Affiliated Managers (AMG)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pro Medicus Limited (PMCUF) and Amgen (AMGN) with bu...

Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (OtherPMCUF) and Amgen (AMGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN) and Alector (ALEC) with bullish sentime...

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Alector (ALEC)

Analysts fell to the sidelines weighing in on Amgen (AMGN) and Airsculpt Technologies (AIRS) with neutral ratings, indicating that the experts are ...

Analysts’ Top Healthcare Picks: Amgen (AMGN), Airsculpt Technologies (AIRS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medtronic (MDT), Pharvaris (PHVS) and Amgen (AMGN) w...

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Pharvaris (PHVS)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. The new Amgen Inc. rollover study, officially titled “An Open-label, Rollove...

Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study

In a report released today, Mohit Bansal from Wells Fargo assigned a Hold rating to Amgen, with a price target of $390.00. Bansal covers the Health...

Wells Fargo Gives a Hold Rating to Amgen (AMGN)

The latest update is out from MetalNRG Plc ( ($GB:AMG) ). Atlas Metals Group has issued 648,497 new ordinary shares of £0.01 each to a third party ...

Atlas Metals issues shares to settle contractual claim and updates voting rights

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has reported a key update on its Phase 3 ROCKET-Outpost st...

Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GIL...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GILD)

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Affiliated Managers (AMG) and Renasant (RNST) with bu...

Analysts’ Top Financial Picks: Affiliated Managers (AMG), Renasant (RNST)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. The Phase 1/1b study “A Phase 1/1b Study Evaluating the Safety, Tolerability...

Amgen Expands Oncology Pipeline With New Phase 1 AMG 436 Study in MSI-H/dMMR Tumors

MetalNRG Plc ( ($GB:AMG) ) has shared an announcement. Atlas Metals Group plc has disclosed a share purchase by non-executive director Christian Sc...

Atlas Metals Director Increases Stake with £10,695 Share Purchase

The latest update is out from Global Asset Management Group ( ($GAMG) ). On March 13, 2026, Global Asset Management Group, Inc. completed a series ...

Global Asset Management Expands Cannabis-Focused Asset Portfolio

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was up 0.34% in Friday’s pre-market trading. Investor...

Invesco QQQ Trust ETF (QQQ) Daily Update, 3/13/2026

Bernstein analyst Courtney Breen maintained a Hold rating on Amgen yesterday and set a price target of $335.00. The company’s shares closed yesterd...

Bernstein Sticks to Their Hold Rating for Amgen (AMGN)

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), fell 0.32% in Thursday’s pre-market trading as rising...

Invesco QQQ Trust ETF (QQQ) Daily Update, 3/12/2026

The Invesco QQQ Trust ETF&nbsp;($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was down 0.02% in Wednesday’s pre-market trading...

Current Quarter	$7.39	Next Quarter	$6.43
Current Year	$30.75	Next Year	$35.22
QoQ Growth	-13.0%	YoY Growth	+14.5%
3Y EPS CAGR	+6.4%	Target Price	$393.57
Consensus	Buy	Upside	+37.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMG	$286.32	0.00%	302.36K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMG	$286.32	0%	302.36K
3
4
5
6

AMG

AMG

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Affiliated Managers Group Inc. Data in Excel

Get Affiliated Managers Group Inc. Data in Excel